Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said the potential of its lead asset will be discussed at a leading medical conference in December.
A poster presentation to the 65th American Society of Hematology (ASH) Annual Meeting in San Diego will outline POLB 001's potential as a treatment for Cytokine Release Syndrome (CRS), a significant complication in cancer immunotherapy.
CRS, varying from mild to life-threatening cases, often requires hospitalisation and can hinder the administration of cancer treatments.
Insights from the POLB 001 LPS human challenge trial will be shared, spotlighting the drug's promise in making cancer immunotherapies more tolerable and broadly available.
The ASH conference is a globally distinguished event, drawing over 25,000 professionals to discuss haematological advancements.
Dr Emma Searle, consultant haematologist and honorary senior lecturer at the University of Manchester, said: "Having this abstract accepted at ASH represents a strong validation of POLB 001's potential in addressing CRS in oncology.
"Cytokine Release Syndrome is highly prevalent among patients receiving immunotherapy for haematological malignancies.
"The positive data from the LPS challenge trial has highlighted that oral treatment of POLB 001 holds great promise in tackling this issue; potentially leading to improved patient outcomes, reduced strain on healthcare systems while making these treatments more accessible to a broader patient population."
For more information on the ASH conference, which takes place on 9 December, click here.